Early biopsychological changes during masculinizing gender-affirming hormone therapy in AFAB transgender individuals: a 4-month prospective study - Report - MDSpire
Advertisement
Early biopsychological changes during masculinizing gender-affirming hormone therapy in AFAB transgender individuals: a 4-month prospective study
Clinical Report: Initial Biopsychological Transformations in AFAB Transgender Individuals
Overview
This study investigates early biopsychological changes in transgender individuals assigned female at birth undergoing masculinizing hormone therapy (GAHT). Significant reductions in anxiety and trauma-related symptoms, along with improvements in quality of life, were observed over the first four months of treatment.
Background
Transgender individuals often face heightened psychological distress, including anxiety and trauma-related symptoms, which can impact their quality of life. Gender-affirming hormone therapy (GAHT) is known to alleviate some of this distress, yet the early biopsychological changes during the initial phase of masculinizing therapy remain poorly understood. Understanding these changes is crucial for optimizing treatment and support for this population.
Data Highlights
Assessment Timepoint
Estradiol Levels
Testosterone Levels
Anxiety (HAM-A)
Trauma Symptoms (TSC-40)
Quality of Life (MANSA)
Baseline
High
Low
High
High
Low
2 Months
Decreased
Increased
Reduced
Reduced
Improved
4 Months
Further Decreased
Further Increased
Significantly Reduced
Significantly Reduced
Significantly Improved
Key Findings
Significant reductions in anxiety and trauma-related symptoms were observed after 4 months of GAHT.
Quality of life measures improved significantly over the treatment period.
Endocrine changes included decreased estradiol and increased testosterone levels.
Associations between hormonal changes and psychological improvements were more pronounced at 4 months compared to earlier assessments.
Psychological improvements were influenced by factors beyond hormonal changes alone.
Clinical Implications
Clinicians should monitor psychological outcomes alongside hormonal changes in transgender individuals undergoing GAHT. Early intervention and support may enhance psychological adaptation during the initial treatment phase, addressing both endocrine and psychosocial factors.
Conclusion
The study highlights the favorable early biopsychological changes associated with masculinizing GAHT in transgender individuals assigned female at birth. Further research is warranted to explore the complex interplay between hormonal and psychological factors during transition.
